Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia 1

Interventions

Cyclophosphamide 85fludarabine phosphate 84Peripheral Blood Stem Cell Transplantation 70Mycophenolic Acid 58Tacrolimus 57Whole-Body Irradiation 55Busulfan 54Antilymphocyte Serum 47Cyclosporine 45Methotrexate 38fludarabine 37Filgrastim 37Melphalan 32Radiotherapy 27Cytarabine 27Etoposide 21Methylprednisolone 20Cord Blood Stem Cell Transplantation 18Azacitidine 18Sirolimus 15Granulocyte Colony-Stimulating Factor 15Flow Cytometry 14Cyclosporins 14thymoglobulin 13Specimen Handling 13Alemtuzumab 13Biopsy 12venetoclax 10Thiotepa 10Decitabine 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myeloproliferative Disorders × zileuton × Other hematologic neoplasm × Clear all
NCT01130688 2015-05-27

Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.

University of Massachusetts, Worcester

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡